SELLAS Life Sciences Group, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter report. SELLAS is a clinical-stage oncology biopharmaceutical company with no approved products or product-sales revenue.
Business and pipeline
The company’s lead candidate, GPS, is a WT1-targeting peptide immunotherapy being tested in the Phase 3 REGAL study for AML maintenance after second remission. Its second candidate, SLS009, is a selective CDK9 inhibitor being developed in relapsed or refractory AML and lymphoma. The company relies on license partners, contract research organizations and contract manufacturers.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Licensing revenue | $0 | $1.0 million |
| Research and development | $24.0 million | $20.3 million |
| General and administrative | $13.9 million | $12.6 million |
| Operating loss | $37.9 million | $42.0 million |
| Net loss | $37.3 million | $41.3 million |
| Net loss per share | $1.34 | $2.13 |
| Cash used in operating activities | $31.4 million | $23.8 million |
Lower net loss largely reflected the absence of the $10.0 million SLS009 in-process R&D charge recorded in 2022; operating expenses excluding that charge increased. R&D rose with clinical-trial, consulting and personnel costs. No product revenue or meaningful product gross margin was reported. Interest income was $0.5 million in 2023.
At December 31, 2023, cash and cash equivalents were $2.5 million (plus $0.1 million restricted cash), current liabilities were $13.7 million, total liabilities $14.2 million, and stockholders’ equity was negative $8.0 million. The filing lists no outstanding borrowings; liabilities primarily include accounts payable, accrued costs and lease obligations. Operating cash use exceeded financing proceeds, and total cash, cash equivalents and restricted cash declined by $14.6 million to $2.6 million.
The auditor’s financial-statement opinion was unqualified, but included a going-concern emphasis. Management said year-end cash, together with the January and March 2024 offerings, would still not fund planned operations for at least 12 months from issuance of the statements. Additional financing is required; none was committed.
Changes, outlook and material items
- REGAL exceeded its target enrollment during Q4 2023; enrollment completion was announced in March 2024. Management estimated the event-driven interim analysis after 60 deaths in the first half of 2024 and final analysis after 80 deaths by year-end 2024. Timing and results remain uncertain.
- In March 2024, SELLAS reported preliminary SLS009 plus azacitidine/venetoclax results from 21 relapsed/refractory AML patients: response rates were 10% at 45 mg weekly, 20% at 60 mg weekly and 50% at 30 mg twice weekly. Median overall survival was not reached. These are preliminary, small-cohort results, not FY 2023 results; further data were expected in Q2 2024.
- SELLAS reported that it commenced binding arbitration against 3D Medicines in December 2023 over, among other matters, $13.0 million in disputed milestone payments and alleged development-effort failures. The outcome and any recovery are uncertain; $191.5 million of potential future milestones under the broader agreement is contingent and not under SELLAS’s control.
- SELLAS raised approximately $9.0 million gross in January 2024 and $20.0 million gross in March 2024. These financings and associated warrants materially increase potential share dilution; the company nevertheless disclosed continuing substantial doubt about its ability to continue as a going concern.
- Nasdaq listing deficiencies disclosed in the filing were reported as cured in March 2024. Management reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor did not attest to ICFR.
Key risks include clinical or regulatory failure, dependence on additional capital, dilution, reliance on single-source manufacturing and external vendors, license and arbitration disputes, and competition, reimbursement and commercialization uncertainty. No specific financial guidance was provided.
Important facts for investors to verify
- Current cash runway and funding needs after the January and March 2024 offerings, including whether subsequent financing is required.
- REGAL interim and final event counts, analysis timing, statistical outcomes and any FDA alignment on a potential BLA.
- Final, independently reviewed SLS009 efficacy and safety data, including biomarker findings and results by dose cohort.
- Status and potential financial impact of the 3D Medicines arbitration and the disputed milestone payments.
- Fully diluted share count and the effects of outstanding warrants, pre-funded warrants and recent offering terms.